← Patent-cliff monitor small molecule ROMVIMZA VIMSELTINIB
Loss of exclusivity April 2045 latest FDA-listed patent expiry
Drug detail Brand name ROMVIMZA Active ingredient VIMSELTINIB Strength 14MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval February 2025 Marketing status RX
Listed patents Patent Expires Type 12686672 April 2045 product 12509443 April 2045 product 12551483 December 2044 product 12528787 December 2044 substance, product 12643883 December 2044 substance, product 12447149 December 2044 product 12617775 December 2044 substance, product 11679110 February 2040 use U-4145 11103507 February 2040 use U-4145 12485120 December 2039 use U-4145 12582655 December 2039 use U-4145 12285430 December 2039 use U-4145 9181223 March 2034 substance, product
Regulatory exclusivity Code Expires NCE February 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.